Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Patent
1998-08-21
2000-12-19
Yucel, Remy
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C07K 1400
Patent
active
061628980
ABSTRACT:
Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. And in some cases both the Rev and the Rex function and are, active in more than one viral species. Such transdominant viral mutants are useful as anti-viral agents to, for example of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g. HIV-1, infection.
REFERENCES:
patent: 4738922 (1988-04-01), Haseltine et al.
patent: 4935372 (1990-06-01), Goh
patent: 4981790 (1991-01-01), Haseltine et al.
patent: 5043262 (1991-08-01), Haseltine et al.
patent: 5871958 (1999-02-01), Cullen
Arya et al., Science, 229:69-73 (1985).
Miller et al., The Operon, CHS, pp. 31-88 (1978).
Ptashne, M., Nature 335:683-89 (1988).
Ratner et al., Nature, 313:277-84 (1985).
Rosen et al., PNAS 85:2071-75 (1988).
Seiki et al., PNAS 80:3618-22 (1983).
Sodroski et al., Science, 229:74-77 (1985).
Sodroski et al., Science, 227:171-73(1985).
Abstract, 90-015165/02, USSH Aug. 8, 1998, U.S. Dept. Health and Human Services.
CA 114(i):3008s, Wong-Stall (1990), NTIS Order No. Pat-Appl-7-306-612.
Goh et al., Science, 227: 1227-1228 (1985).
Franza et al., The Control of Human Retrovirus Gene Expression, Cold Spring Harbor Laboratory, (1988).
Arrigo et al., J. Virol. 63, 4875-4881 (1989).
Baltimore, Nature 335, 395-396 (1988).
Chang et al., Science 249, 614-615 (1990).
Cochrane et al., J. Virol. 63, 4438-4440 (1989).
Cochrane et al., Virology 173, 335-337 (1989).
Cullen, Cell 46, 973-982 (1986).
Cullen, Meth. in Enzym. 152, 684-704 (1987).
Cullen et al., J. Virol. 62, 2498-2501 (1988).
Cullen, Nature 351, 698-699 (1991).
Culliton, Science 246, 746 (1989).
Daly et al., Nature 342, 816-819 (1989).
De et al., Nucleic Acids Res. 17, 2142 (1989).
Dokhelar et al., J.Acquir.Immune Defic.Synd. 2, 431-440 (1989).
Endo et al., Virus Genes 3, 99-110 (1989).
Feinberg et al., Cell 46, 807-817 (1986).
Felber et al., BIOSIS 37083067 (1989) (abstract only).
Friedman et al., Nature 335, 452-454 (1988).
Friedmann, Science 244, 1275-1281 (1989).
Green et al., Cell 58, 215-223 (1989).
Haigh et al., Nature 344, 257-259 (1990).
Hanly et al., Genes and Develop. 3, 1533-1544 (1989).
Haseltine, Scien.Amer., Oct. 1988, 52-62.
Hauber et al., J.Virol. 62, 4801-4804 (1988).
Herskowitz, Nature 329, 219-222 (1987).
Hidaka et al., EMBO J. 7, 519-523 (1988).
Hughes et al., J.Cell.Biochem.Supp. 13B, 276 (1989).
Itoh et al., Oncongene 4, 1275-1279 (1989).
Kubota et al., Biochem.Biophys.Res.Comm. 162, 963-970 (1989).
Lawson et al., Biotechnology 8, 127-134 (1990).
Lehn, Bone Marrow Transplant 1, 243-258 (1987).
Malim et al., Nature 335, 181-183 (1988).
Malim et al., Nature 338, 254-257 (1989).
Malim et al., Fifth Intl.Conf. on AIDS, Jun. 4-9, 1989 Montreal, Que., Canada.
Malim et al., Cell 58, 205-214 (1989).
Malim et al., Proc.Natl.Acad.Sci.USA 86, 8222-8226 (1989).
Malim et al., Cell 60, 675-683 (1990).
Manzari et al., Proc.Natl.Acad.Sci.USA 80, 1574-1578 (1983).
Mermer et al., Nucl.Acids Res. 18, 2037-2044 (1990).
Mitsuya et al., Science 249, 1533-1544 (1990).
Miyoshi et al., Nature 294, 770-771 (1981).
Newmark, Nature 342, 221 (1989).
Olsen et al., Science 247, 845-848 (1990).
Perkins et al., J.Acquir.Immune Defic.Syndr. 2, 256-263 (1989).
Peterlin et al., Biotechnology 6, 794-799 (1988).
Rimsky et al., Nature 341, 453-456 (1989).
Sadaie et al., Science 239, 910-913 (1988).
Seiki et al., Proc.Natl.Acad.Sci. USA 85, 7124-7128 (1988).
Siomi et al., Cell 55, 197-209 (1988).
Sodroski et al., Science 225, 381-385 (1984).
Sodroski et al., Nature 321, 412-417 (1986).
Staeheli, Tibtech 9, 71-72 (1991).
Tada et al., Proc.Natl.Acad.Sci. USA 87, 3479-3483 (1990).
Temin, Science, 246, 983 (1989).
Terwilliger et al., J.Virol. 62, 655-658 (1988).
Therre, Biofutur Mar. 1990, 21-22 (1990).
Trono et al., Cell 59, 113-120 (1989).
Wachsman et al., Science 235, 674-677 (1987).
Zapp et al., Nature 342, 714-716 (1989).
Zhou et al., Virus Genes 3, 153-158 (1989).
Amersham International plc, Oligonucleotide-directed in vitro mutagenesis system version 2, 1-32 (1988).
Scrip No. 1439, 23 (1989).
Scrip No. 1441, 18 (1989).
Scrip No. 1465, 21 (1989).
Rosenblatt et al., Science 240, 916-919 (1988).
Bahner et al., "Comparison of trans-Dominant Inhibitory Mutant Human Immunodeficiency Virus Type 1 Genes Expressed by Retroviral Vectors in Human T Lymphocytes", Journal of Virology, pp. 3199-3107 (Jun. 1993).
Bevec et al., "Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator", Proc.Natl.Acad.Sci. USA, vol. 89, pp. 9870-9874, (Oct. 1992).
Ferber et al., "Mechanism of function of the HIV-1 Rev protein", Int.Conf.AIDS, Jun. 20-23 (1990).
Fox et al., "Genetic Modification of Human Peripheral Blood Lymphocytes with a Transdominant Negative Form of Rev: Safety and Toxicity", Human Gene Therapy 6:997-1004 (Aug. 1995).
"Gene Therapy for AIDS," Scrip No. 2124, p. 19 (Apr. 30, 1996).
Green et al., "Mutational Analysis of HIV-1 Tat Minimal Domain Peptides: Identification of Trans-Dominant Mutants that Suppress HIV-LTR-Driven Gene Expression", Cell. vol. 58, 215-233, Jul. 14, 1989.
Malim et al., "Stable Expression of Transdominant Rev Protein in Human T Cells Inhibits Human Immunodeficiency Virus Replication", J.Exp.Med 176 pp. 1197-1201 (1992).
Malim et al., "Trans-Dominant Rev Mutants Can Protect T Cell Lines from HIV-1 Infection Without Disturbing Normal Function", J.Cell.Biochem.Suppl. 16E p. 33, Abstr. Q539 (1992).
Malim et al., "Transdominant Rev Protein Inhibits HIV Replication Without Affecting T Cell Function", Clin.Res. 40, Abstr., p. 253A (1992).
Mermer et al., "Identification of trans-dominant HIV-1 rev protein mutants by direct transfer of bacterially produced proteins into human cells", Nucleic Acids Research, vol. 18, No. 8, 2037.
Ragheb et al., "A Unified Gene Therapy Approach to the Treatment of AIDS," J.Cell Biochem.Suppl. 16E, p. 86, Abstract Q549 (1992).
Vandendriessche et al., "Inhibition of Clinical Human Immunodeficiency Virus (HIV) Type 1 isolates in Primary CD+T Lymphocytes by Retroviral Vectors Expressing Anti-HIV Genes," Journal of Virology, p. 4045-4052 (Jul. 1995).
Woffendin et al., "Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients", Proc.Natl.Acad.Sci. USA, vol. 93, pp. 2889-2894 (Apr. 1996).
Woffendin et al., "Nonviral and viral delivery of a human immunodeficiency virus protective gene into human T cells," Proc.Natl.Acad.Sci. USA, vol. 91, pp. 11581-11585 (Nov. 1994).
"Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," Orkin and Motusky, Co-chairs, (Dec. 7, 1995).
Feinberg et al., AIDS Res.and Human Retrovir, 8(6):1013-1022 (1992).
Johnston et al., Science 260:1286-1293 (1993).
Gilboa et al., Trends in Genetics 10(4):139-144 (1994).
AIDS Agenda--Jun. 1996 (p. 6 (NIAID).
Rosenblatt et al., Science 240:916-919 (1988).
Rimsky et al., Nature 335:738-740 (1988).
Duke University
Furman Diane E.
Yucel Remy
LandOfFree
Mutant Rev transdominant repressors of HIV replication does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutant Rev transdominant repressors of HIV replication, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant Rev transdominant repressors of HIV replication will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-272020